Passage Bio
$13.199876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$13.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.31 (+2.41%) As of 2:17 PM EDT today
Why Robinhood?
You can buy or sell Passage Bio and other stocks, options, ETFs, and crypto commission-free!
About PASG
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. Read More The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA. The listed name for PASG is Passage Bio, Inc. Common Stock.
Employees
20
Headquarters
Philadelphia, Pennsylvania
Founded
2017
Market Cap
594.51M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
229.80K
High Today
$13.55
Low Today
$12.64
Open Price
$13.40
Volume
128.82K
52 Week High
$38.23
52 Week Low
$8.09
PASG Earnings
-$1.00
-$0.67
-$0.33
$0.00
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Nov 12, Pre-Market